The six companies that have priced initial public offerings so far banked a median of $287.5 million, a figure far surpassing ...
New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry ...
Net profit recorded RMB222.0 million, a significant turnaround from a year ago Adjusted Non-IFRS net profit recorded RMB314.6 million, a YOY increase of nearly 50.6%. SHANGHAI, March 27, 2025 ...
SPDR S&P Biotech ETF (NYSEARCA:XBI) is built around a deceptively simple idea: give every biotech company roughly equal footing, regardless of size. That equal-weight structure separates it from ...
Shares Biotechnology ETF (IBB) gives investors biotech exposure through large, established drug developers rather than smaller speculative names. That structure can offer more earnings visibility, but ...
Investment giant KKR & Co. Inc. (NYSE: KKR) is advising investors to look past the crowded trades of the U.S. large-cap market for the next phase of growth. In its “High Grading” Outlook for 2026, the ...
DUBLIN, Ireland, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Trinity Biotech plc (TRIB), a commercial-stage biotechnology company focused on human diagnostics and diabetes management solutions, including ...
For research scientists and laboratory professionals navigating increasingly complex experimental challenges, access to ...
Biotech stocks surged in 2025, driven by FDA approvals, M&A activity, and rising longevity investment. Explore key trends, top-performing sectors, and what’s next for biotech investors.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results